This site is intended for Healthcare Professionals only

Managing moderate to severe hay fever

Dymista® Control nasal spray is the first Pharmacy-only (P) nasal spray in the UK that contains a combination of an antihistamine and a corticosteroid. It is indicated to relieve symptoms of moderate to severe seasonal allergic rhinitis (AR), or hay fever, in adults if monotherapy with either intranasal antihistamine or corticosteroid is not considered sufficient.1

Learning objectives

  • Understand how Dymista® Control differs from other treatment options for hay fever available from the pharmacy

  • Recognise when Dymista® Control may be suitable to help relieve symptoms of hay fever

  • Provide advice on the appropriate use of Dymista® Control

This training module is not intended to replace the Dymista® Control nasal spray Risk Minimisation Material (RMM). You can access the Pharmacy Essential Guide (RMM) through the link provided at the end of this module.

For key points about Dymista® Control, please refer to the summary card.


Product information and information on adverse event reporting is available at the end of the module.

Content developed by Viatris, working with CIG Healthcare Partnership.
© 2025 CIG Healthcare Partnership

UK-DTC-2025-00003 March 2025

Change privacy settings